Ensysce Biosciences, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- D. Lynn Kirkpatrick
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 7946 Ivanhoe Avenue La Jolla CA United States of America 92037
- IPO Date
- Mar 14, 2018
- CIK
- 0001716947
- Website
- ensysce.com
- Similar Companies
- Business
- Ensysce Biosciences, Inc. (NASDAQ:ENSC) is a clinical-stage pharmaceutical company that develops abuse-deterrent and overdose-resistant prodrug technologies for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. The company leverages its proprietary Trypsin Activated Abuse Protection (TAAP) platform, which creates tamper-proof oral prodrugs activated only in the small intestine to prevent abuse via snorting, extraction, injection, or chewing; and its Multi-Pill Abuse Resistant (MPAR) platform, which adds overdose protection by inhibiting activation when multiple pills are ingested, combining TAAP prodrugs with a trypsin inhibitor such as nafamostat. Lead product candidates include PF614, a TAAP-based extended-release oxycodone prodrug for moderate-to-severe chronic pain with FDA Fast Track and Breakthrough Therapy designations; PF614-MPAR, an enhanced version providing both abuse and overdose resistance; and nafamostat, under development for infection and pulmonary diseases beyond its overdose protection role. Ensysce operates in the biotechnology sector, targeting patients with high unmet needs in pain management, oncology, and related areas, with universal application potential across oral prescription drugs prone to abuse. Originally incorporated in Delaware in 2003 as PharmacoFore, Inc., renamed Signature Therapeutics in 2012, and rebranded Ensysce Biosciences following a 2021 business combination, the company maintains headquarters at 7946 Ivanhoe Avenue, Suite 201, La Jolla, California 92037. Recent developments include initiation of the pivotal Phase 3 PF614-301 trial in July 2025 for post-abdominoplasty pain; positive FDA feedback on Phase 3 design with enrollment planned for 2Q2025; a $14 million multi-year non-dilutive NIH/NIDA grant in 2024 to support PF614-MPAR studies and NDA preparation; an August 2024 $5 million financing; a November 2025 $4 million convertible preferred stock financing with up to $16 million more available; a key manufacturing and commercialization partnership with Purisys LLC (a Noramco subsidiary); engagement of Rho, Inc. for trial management; and plans for PF614 NDA submission in 2026 followed by potential commercialization.
Ensysce Biosciences Reports First Quarter 2026 Financial Results
Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam
Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study
Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs
Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results
Ensysce Biosciences, Inc. (NASDAQ:ENSC) Short Interest Down 59.3% in March
Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans
Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology
Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic Review
Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value
Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events
Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain
Ensysce Biosciences Expands Global Opioid Patent Portfolio
Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection
Ensysce Biosciences, Inc. (ENSC) Shareholder/Analyst Call Prepared Remarks Transcript
Ensysce Biosciences Issues Annual Shareholder Letter
Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)
Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid
Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology